Outcome of the board meeting held on 12th February, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech's Board of Directors approved its standalone and consolidated unaudited financial results for Q3 FY26 (quarter ended December 31, 2025) and the nine months ended on that date, which were reviewed by statutory auditors A N S K & Associates. On a standalone basis, Q3 revenue from operations rose to Rs. 5,650.57 lakhs versus Rs. 3,827.58 lakhs in Q3 FY25, while net profit jumped to Rs. 786.82 lakhs versus Rs. 380.19 lakhs, translating to an EPS of Rs. 9.52. For the 9-month period, revenue climbed to Rs. 15,735.68 lakhs from Rs. 12,128.15 lakhs and net profit rose to Rs. 2,089.15 lakhs (EPS of Rs. 25.28) versus Rs. 1,450.50 lakhs in the prior year. The consolidated Q3 net profit stood at Rs. 852.86 lakhs, including a Rs. 66.04 lakh share of profit from associates Peptech Biosciences and Titan Media.
Strong year-on-year growth in both revenue (about 48% up in Q3) and profits (more than doubled in Q3) signals robust operational momentum and is a positive for shareholders in the near term, though this is only a limited-review result and not a final audited figure.